N4 Pharma (LSE:N4P) has released an operational update outlining continued progress across its Nuvec® nanoparticle platform, including an advancing collaboration with the University of Strathclyde. The partnership is moving toward key study milestones expected to take place in 2026.
The company is focused on highlighting the advantages of its Nuvec® technology compared with conventional lipid nanoparticles, particularly its enhanced stability profile. This feature is viewed as critical to the development of N4 101, its lead anti-inflammatory candidate, and to supporting future commercial partnerships. Recent progress includes successful preclinical results demonstrating oral delivery and efficacy in models of inflammatory bowel disease and non-small cell lung cancer.
N4 Pharma expects a steady stream of data-led updates as development continues and has further reinforced its intellectual property position through additional patent filings. Management believes these advances strengthen the platform’s differentiation and long-term commercial potential.
More about N4 Pharma
N4 Pharma plc is a UK-based biotechnology company developing Nuvec®, a proprietary gene delivery technology designed to support next-generation RNA therapeutics. The company is focused on oncology and inflammatory disease applications, aiming to improve stability and targeting compared with existing delivery systems.
Leave a Reply